RefleXion Medical announced today that it entered into a non-exclusive, worldwide licensing agreement with Mirada Medical.
The agreement allows for the integration of Mirada’s RegEngine image registration algorithms into the RefleXion X1 treatment planning software, aligning patient anatomy between different imaging modalities or between radiotherapy treatments.
“Day-of-treatment modifications, called adaptive radiotherapy, are critical for responding to changes in patient anatomy that occur as a result of cancer treatment, and to lowering toxicity to improve outcomes,” RefleXion Chief Business Officer Thorsten Melcher said in a news release. “In challenging patients, such as those with metastatic disease where more than one tumor may be treated, adaptation requires robust tools such as Mirada’s sophisticated RegEngine software, so that clinicians can quickly assess patient anatomy and, in the future their biology, to implement changes to the treatment plan.
“Mirada’s extensive industry experience and development expertise were key factors in our decision to pursue this agreement.”
Mirada designed its image registration algorithms to align the images of a patient’s anatomy taken at different points in time using different imaging modalities. For radiation oncology, it aids in the critical registration of the tumor target treatment and the nearby anatomy to avoid. Precise targeting may also result in lowering toxicity and improving outcomes, according to the release.
RefleXion develops its biology-guided radiotherapy (BgRT) technology to use a PET radiotracer to create a unified motion management solution for one or multiple tumors, producing emissions that signal cancer location as the tracer binds to tumor cells.
BgRT uses real-time biological information to deliver a tracked radiation dose to the cancer. RefleXion said that integrating RegEngine into BgRT will allow clinicians to rapidly adapt the daily treatment plan by precisely registering images and image components that are crucial for treatment planning and dose calculation.
“Our relationship with RefleXion is another example of our ability to work with cutting edge oncology companies,” Mirada CEO Jon DeVries said. “RefleXion’s biology-guided radiotherapy has the potential to offer a new treatment option for patients with all stages of cancer, and we are excited and proud to have RegEngine selected as a key component of the treatment planning process in this exciting novel technology.”
